NASDAQ · ENTA
Healthcare · Biotechnology
$12.70
Down-$0.18 (-1.42%)
Updated Sep 17, 2026, 8:59 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ENTA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ENTA.
ENTA research
Company profile and research snapshot.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | JP Morgan | Overweight | — |
| Sep 30, 2025 | WestPark Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 1, 2026
WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:
Benzinga · Aug 10, 2026
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
Benzinga · Jul 2, 2026
-SEC Filing
Benzinga · Jun 23, 2026
https://news.bloomberglaw.com/us-law-week/pfizer-keeps-win-in-patent-lawsuit-aimed-at-paxlovid-antiviral
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENTA.
